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Summary: The retinoids are the natural and synthetic analogues of retinol or vitamin A. These molecules are
able to modulate differentiation and proliferation processes in several cell types. The presence of retinoids is
essential for inducing or maintaining the differentiation of epithelial cells. On the other hand, when excess
retinol is added to the culture medium, the differentiation of some mesenchymal cells is impaired. Retinoids
also promote the differentiation of carcinoma cells of various origins: embryonal carcinoma, leukaemic and
melanoma cells. While their effect on the proliferation of normal cells appears variable, these molecules inhibit
the growth of cells treated with a tumoural promoter, or spontaneously transformed cells, and they prevent
tumour promotion. Various mechanisms of action might be involved: retinoids could act at the level of the
genome with or without the participation of their binding proteins. They might also influence glycoconjugate
biosynthesis and interact, through certain glycosylation reactions, with growth factor receptors. The role of
vitamin A and its structural analogues in cell differentiation and growth is of great therapeutic interest.
After a brief reminder of the structure and metabolism
The neoplastic process is characterized by an alter- of the retinoids we shall go on to discuss first the
ation of the differentiated histological state of cells effect of these compounds on the differentiation of
towards metaplastic and anaplastic forms and is as- various cell types (of epithelial, mesenchymal and
sociated with cellular proliferation which escapes the cancerous origin). We shall then study the influence
usual homeostatic control systems. of the retinoids on the proliferation of normal and
,.,-., I L L j ^ n -XL cancerous cells and those treated by promoters. Fi-While cancer logy has been concerned essentially with „ , „ ,. , . ,
 r
., . " r ,· · n j LI r r nail v, we shall discuss the various modes of actionthe treatment of clinically detectable forms of neo- , . , , , ,ι .. "j. j. , . . j " which have been suggested,plastic disease, numerous studies are being carried out
at present aimed at identifying substances which
might be able to act before the neoplastic process _ _ _ ., _Α Λ , _ . _ . . ..
u
&
 Λ j·«·" *· *· The Retinoids: Structure and Metabolismbecomes invasive, i.e. to act on the differentiation
and proliferation processes of the cells concerned. One Lotan (1) defines as 'vitamin A' or retinoids a group
of these substances, vitamin A — and its derivatives, of substances capable of restoring normal growth in
the retinoids — has been studied extensively and we retinol-deficient experimental animals. The general
propose a review of the relevant work. formula of these compounds comprises a cyclic struc-
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ture, a central polyenic chain and a polar terminal
group. The most frequently used molecules, natural
or synthetic, are described in figure 1.
Absorption and transport
The natural retinoids are ingested in the food in the
form of retinol, retinyl esters, retinoic acid and a
provitamin, ß-carotene. The retinyl esters are hydro-
lysed by enzymes1) present in the pancreas and brush
border membrane; retinol and carotene are then ab-
sorbed by the intestinal mucosa. In the enterocytes,
ß-carotene is split into two molecules of retinal which
are then reduced; the retinol is reesterified and the
retinyl esters incorporated into the chylomicrons. The
latter are then degraded into remnants and captured
by the liver. The retinyl esters are stored in the he-
patocytes and perisinusoidal cells (2) and hydrolysed
according to the requirements of the organism. The
retinol is then transported towards the tissues in the
form of a circulating complex associating retinol,
transthyretin and retinol binding protein (3). Retinol
binding protein consists of a polypeptide chain of
MT = 21 000 and possesses a binding site for retinol.
In the plasma, one molecule of retinol binding protein
associates with one molecule of transthyretin, a sym-
metrical tetramer composed of 4 identical subunits,
each of molecular weight 55000 and possessing a
binding site for retinol binding protein. Under phys-
iological conditions, the transthyretin/retinol binding
protein ratio is a constant 2.5/1 in the plasma and
nearly all the circulating retinol binding protein is
bound to transthyretin.
Retinyl esters are only present in very low concentra-
tions in the plasma, but if intake is excessive and the
liver storage capacity becomes saturated, the retinyl
esters circulate bound to lipoproteins.
Finally, retinoic acid and its structural analogues are
transported, following absorption, by the portal vein.
They are not stored but circulate in the plasma bound
to serum albumin.
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Fig. 1. Principle retinoids studied
Capture and intracellular transport
Retinol binding protein binds to specific membrane
receptors: the retinol then passes into the cell and the
retinol binding apoprotein is released (4). The cell
transport mechanism of the other retinoids is little
known.
In the cytosol retinol binds to a specific protein,
cellular retinol binding protein present in several cell
types. A cytosolic receptor for retinoic acid, cellular
retinoic acid binding protein is also present in several
organs in man and animals. Cellular retinoic acid
binding protein is, however, less widely distributed
than cellular retinol binding protein and the cellular
retinol binding protein/cellular retinoic acid binding
protein ratio varies greatly from one type of tissue to
another (2).
Cellular retinol binding protein and cellular retinoic
acid binding protein receptors have been detected and
quantified through their ability to bind [3H]retinol
and [3H]retinoic acid. By way of an example, the
concentrations of cellular retinol binding protein
found in various organs of humans and rats are given
in table 1. The presence of specific cellular receptors
for retinol and retinoic acid has also been described
in certain neoplastic tissue, notably in tumours of the
skin, breast and colon and in human and murine
embryocarcinomas. Kung (5), Ong (6), Mein a (7) and
Palan (8) have found larger quantities of binding
protein in cancerous tissue thanYn normal tissue (cel-
lular retinoic acid binding protein: 5.6 and 35.0 mmol/
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Tab. 1. Amounts of cellular retinol binding protein (CRBP) in
various organs of man and the rat (6,7).
Organ CRBP ^g/g protein)
Testicle
Ovary
Liver
Kidney
Lung
Spleen
Heart
Breast
Skin
Smooth muscle
Man
847
1226
243
67
41
53
27
19
16
9
Rat
88
26
97
115
76
21
8
4
15
mg of protein in normal and cancerous tissue respec-
tively, from the rat mammary gland). In addition,
Sklan & Lotan (9) have shown the presence of a high
molecular weight lipoprotein aggregate bearing both
retinol and retinoic acid in the cytosol of various
human and murine tumour cells.
Neither cellular retinol binding protein nor cellular
retinoic acid binding protein show tissue specificity.
These molecules have similar molecular weights (cel-
lular retinol binding protein: Mr = 14600, cellular
retinoic acid binding protein: Mr = 14000) and are
composed of a single protein chain. Their composition
is similar in terms of the amino acids they contain
and certain sequences are shared. They are, however,
immunologically different from each other and from
plasmatic retinol binding protein. Cellular retinol
binding protein possesses a high affinity for retinol
and its cis-isomers (Kd = 16 χ 10~9 mol/1), but not
for retinal and retinoic acid. One receptor molecule
binds one ligand molecule. Similarly, cellular retinoic
acid binding protein binds retinoic acid with a high
specificity and affinity. The dissociation constant is
approximately 10~8 to 10~9 mol/1.
The work of Takase et al. (10) on nuclei isolated from
the liver of rats deficient in receptors has shown the
presence of a specific and saturable bond between the
[3H]retinol-cellular retinol binding protein complex
and such nuclei. In contrast, the binding of free
[3H]retinol in the same experimental conditions is
nonspecific and nonsaturable. Experiments with
[3H]retinoic acid-cellular retinoic acid binding protein
and isolated nuclei of several cell models also show
specific interactions between the retinoid-receptor
complex and certain sites of the nucleus (11). These
results suggest that following the formation of the
retinoid-receptor complex there is a phenomenon of
translocation of the cytosol towards certain specific
sites of the nucleus which are distinct for the two
molecules. The retinoids would then dissociate from
their binding proteins. Moreover, very recently, using
a cell line from a mammary carcinoma, MCF7, Pet-
kovich et al. (12) cloned a cDNA located on chro-
mosome 17 encoding a nuclear protein receptor that
binds retinoic acid, but not retinol, with high affinity.
However, the way in which cellular retinoic acid bind-
ing protein and this human retinoic acid receptor
(hRAR) participate in the mechanism of action of
retinoic acid remains undetermined.
Intracel lular metabolism
Retinol can follow various metabolic pathways,
whether or not it is bound to cellular retinol binding
protein. It can first be converted to a glucurono-
conjugate in the presence of UDP glucuronate. Re-
tinol can also form esters and undergo dehydration
giving rise to anhydroretinol. Finally, it can be oxi-
dized into retinal in a reversible fashion, then irrev-
ersibly into retinoic acid; the reaction is catalysed by
alcohol dehydrogenase in the presence of NAD*. The
capacity of a cell to produce retinoic acid depends on
the cell type and the experimental conditions (13).
Napoli (14) showed that porcine kidney cells are able
to generate retinoic acid from retinol. This property
was not observed in similar experiments with certain
lines of embryocarcinoma cells (15).
Retinoic acid is itself degraded in the microsomes
(14). Its metabolism is complex: under the effect of
an epoxidase, it forms a 5,6-epoxyretinoic acid which
is then transformed into a 5,8-oxo derivative. Finally,
retinoic acid can undergo various oxidative reactions,
forming oxo and hydroxylated derivatives found in
the urine and stools.
Effects of Retinoids on the Differentiation of Normal
and Cancerous Cells
Epithelial cells
Vitamin A and its structural analogues play an im-
portant role in the establishment and maintenance of
the differentiation of epithelial cells as shown both in
vivo by experiments in healthy and deficient animals
and in vitro using cultures of cells or explants in
media lacking or supplemented with retinol.
In vivo — The study of goblet cells from normal or
vitamin Α-deficient rats
Rojanapo (16) and Olson (17) studied the differentia-
tion of germ cells in fragments of the duodenal crypt
glands of control and vitamin A-deflcient rats. In
J. Clin. Chem. Clin. Biochem. / Vol. 26,1988 / No. 8
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normal conditions these cells migrate along the crypt
gland while transforming into oligomucous cells and
subsequently into mucus-producing goblet cells. A
defiency in vitamin A produces a 35% reduction in
the number of goblet cells from the fourth day on-
wards. The authors also observed a reduction in the
incorporation of [14C]fucose into the glycoproteins of
the deficient animals.
In vitro — Morphological studies of cells cultured in
the presence or absence ofretinol
Using tracheal explants from female rats, the authors
show (18) that in the absence of vitamin A, the tra-
cheal epithelium eventually acquires a squamous as-
pect and begins to produce large quantities of keratin,
whereas explants maintained in normal medium con-
taining a volume fraction of 0.1 horse serum, i.e.
48 χ 10~9 mol/1 of retinol show no signs of squamous
metaplasia and are either ciliated or not. In retinol
supplemented medium (7 χ 10~6 mol/1), the epith-
elium is hyperplasic and shows increased secretory
activity (with an increased number of secretory gran-
ules). Experiments conducted by Hardy (19) on ex-
plants of fetal mouse skin showed that the normal
differentiation of the epidermis was altered by the
presence of excess retinol in the culture medium: on
the tenth day, in the presence of 21 χ 10~6 mol/1 of
retinol, the basal lamella is discontinuous, the corneal
layer shows vacuoles, and the desmosomes and tono-
filaments are greatly reduced in number. The keratin-
ization process of new-born Balb/C mouse epidermal
cells is also inhibited when the culture medium con-
tains excessive amounts of retinyl acetate (38 χ 10~6
mol/1) (20).
It therefore appears that the absence ofretinol favours
squamous metaplasia: keratinized cells replace secre-
tory cells (21). There is also an increase in mitotic
activity. These factors favour the development of neo-
plastic lesions. However, while the retinoids are es-
sential to the maintenance of normal differentiation,
an excess of retinol in the culture medium of cuta-
neous epithelia inhibits the keratinization process and
causes an overall disorganization of the cells which
attain a certain degree of mucous metaplasia.
Mesenchymal cells
The effects of a lack or excess of vitamin A have been
studied on the bone and cartilage of various animals
(22, 23). A lack of retinol inhibits the differentiation
of the osteoclasts but does not reduce osteoblastic
activity. An excess of vitamin A appears to increase
the resorption of the cartilage, thus increasing the risk
of fracture.
In organ culture experiments, high doses of vitamin
A lead to the destruction of the tracheal cartilage in
hamsters (24) and of the articular cartilages in pigs
(25) (due to the synthesis and release of lysosomal
enzymes which destroy the extracellular matrix). The
addition of 9.6 μπιοΐ/ΐ of retinoic acid to the culture
medium of mouse embryo mesenchymal cells (26)
inhibits the formation of cartilage: on the fourth day,
the cells, which remain closely packed together — the
extracellular spaces contain fine bands of collagen —
retain the cytoplasmic characteristics of pre-cartila-
genous cells. This inhibitory effect, which could be
mediated by cellular retinoic acid binding protein, is
not due to a toxic effect of retinoic acid, as shown by
the study of cell viability by the trypan blue exclusion
technique. Pennypacker (27) observed a decrease in
proteoglycan synthesis in cultures treated with reti-
noic acid, accompanied by an increase in the glyco-
sylation of cell surface glycoproteins.
Several lines of evidence corroborate the view that in
the chick embryo limb bud, retinoic acid could act as
a morphogen (28). Morphogens are the signal sub-
stances to which cells respond, at varying concentra-
tions, by adopting different pathways of differentia-
tion. Saunders & Gasseling (29) showed that the pos-
terior margin of the chick embryo limb bud grafted
to the anterior side induced the development of a
second set of digits symmetrical to the original set.
This grafted zone, called the zone of polarizing activ-
ity (ZPA), is thought to diffuse a morphogen meta-
bolised by the competent tissue, thus forming a con-
centration gradient. Retinoic acid, which forms a con-
centration gradient across the limb bud (30), could
be the local chemical mediator since exogenous reti-
noic acid produces duplications exactly like ZPA
grafts. The endogenous retinoic acid could be synthe-
sized from retinol which does not present morpho-
genic properties. The cellular retinoic acid binding
protein found in the ZPA at a concentration of 10~5
molecules per limb bud cell might mediate the effects
of retinoic acid. However, the biochemical mechanism
of the action of retinoids as morphogens has not yet
been elucidated. The retinoid could be the first step
in the morphogen response.
Embryonal carcinoma cells
These are the undifferentiated stem cells in teratocar-
cinoma. Several lines of embryonal carcinoma cells
(EC cells) of murine and human origin have been
isolated and cultured (31). The F9 cell line of tera-
tocarcinoma cells undergoes only limited spontaneous
differentiation under normal culture conditions. Ac-
cording to Strickland & Mahdavi (32), retinoic acid
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(10~6 to 10~9 mol/1) is capable of inducing the differ-
entiation of embryonal carcinoma cells of the murine
cell-line F9: following 7 days' incubation in the pres-
ence of retinoic acid, the cells acquire an endodermic
morphology and synthesize new forms of collagen.
The membrane antigen SSE Al, characteristic of mu-
rine embryo carcinoma cells and revealed by immu-
nofluorescence in the presence of monoclonal anti-
bodies, disappears from almost all the cells after 7
days' treatment. Retinoic acid treatment (0.1 μιηοΐ/ΐ)
of F9 cells also causes a progressive increase in cy-
tosolic and plasma membrane cyclic AMP-dependent
protein kinases (33). Furthermore, dibutyryl cAMP
treatment of endodenn-like cells generated by retinoic
acid enhances the synthesis of basement membrane
components such as laminin and collagen IV. Wang
& Gudas (34), using blot hybridization techniques
showed that retinoic acid causes an increase in laminin
B mRNA levels.
 2 Microglobulin, not synthesized by
undifferentiated cells, was used by Eriksson et al. (35)
to estimate the change in the phenotype of the retinoic
acid-treated F9 cells. The amount of
 2 inicroglobulin
found in the cell medium increases with the concen-
tration of retinoic acid (10~6 to 10~10 mol/1) but not
with retinol used in the same concentration range.
The expression of
 2 inicroglobulin has been examined
in F9 cells: no
 2 microglobulin mRNA is detected in
undifferentiated cells, but it becomes detectable dur-
ing differentiation. Other changes in gene expression
have been demonstrated during the F9 differentiation
process: Griep & DeLuca (36) have examined the
action of retinoic acid on the expression of the on-
cogene c-myc — this gene is known to be amplified
in HL 60 cells. Its expression is decreased after retirioic
acid-induced differentiation: the authors observed a
46% decrease in c-myc mRNA in F9 cells 3 hours
after retinoic acid treatment.
Many studies have demonstrated that retinoic acid is
more efficient than retinol in changing the F9 pheno-
type. The greater hydrophobicity of retinol would
explain its binding to lipid bilayers and thus the dif-
ference in the capacity of the two retinoids to induce
differentiation. However, undifferentiated F9 cells
contain low concentrations of the two retinoid bind-
ing proteins, cellular retinol binding protein and cel-
lular retinoic acid binding protein. Retinoic acid treat-
ment promotes the intracellular accumulation of cel-
lular retinol binding protein and cellular retinoic acid
binding protein (35); thus, increased levels of retinoid
binding proteins would reflect the novel phenotype of
F9 differentiated cells. Cells of the murine line PCC4
aza 1R, the so-called 'pluripotent' and nulli SCCI, or
'nullipotent' cells, i.e. incapable of undergoing spon-
taneous differentiation, proliferate and form aggre-
gates when tissue culture dishes are previously coated
with a solution of 2% agarose. Jetten et al. (37) and
Sherman (38) observed a certain maturation induced
by retinoic acid (10~5 to 10"9 mol/1): certain nulli
SCCI cells grown in aggregates became differentiated,
and the proportion of aggregates containing differ-
entiated pluripotent cells increased. The retinoic acid
effect is concentration-dependent; the viability of the
cells has been verified. Furthermore, the authors de-
tected plasminogen activator production by differen-
tiated cells after 2 days' incubation with retinoic acid:
36% of aggregated nulli SCCI cells acquire plasmin-
ogen activator activity. In response to retinol, nulli
SCCI cells differentiate to a modest extent and PCC4
aza 1R not at all; moreover, retinol is toxic for PCC4
aza l R cells at a higher concentration than 10~7 mol/1
for a few days.
Sherman (39) used a technique for the transplantation
of control and retinoic acid-treated carcinoma cells
into mice and observed no external sign of tumour
growth in six of eight mice injected with retinoid-
treated PCC4 aza 1R cells, even after 100 to 200 days.
Palpable tumours appeared in all eight mice receiving
control cells within 10 to 12 days. Finally, mice were
inoculated into the flank with 106 to 6 χ 106 PCC4
aza I cells then treated by 10 daily 20 μΐ intra-tum-
oural injections of all-trans retinoic acid (0.6 μιηοΐ/ΐ)
dissolved in dimethylacetamide (40): on day 11, the
treated tumours showed nearly complete differentia-
tion into mainly fibrillar neuroepithelium.
Retinoic acid-induced differentiation of nulli SCCI
and PCC4 aza 1R EC cells is mediated by cellular
binding proteins. Translocation of binding protein
molecules from cytoplasm to nucleus in response to
the uptake of retinoids by the cell has been demon-
strated by the detection of binding activity in nuclear
fractions (41). When retinoic acid and retinol are
introduced through their binding proteins, they bind
to EC nuclei in a specific and saturable manner. Thus,
the binding of [3H]retinoic acid-cellular retinoic acid
binding protein to EC nuclei is maximal after 30 min
and stable for two hours (41). Specific binding of
[3H]retinol-cellular retinol binding protein appears to
be slower. If cytosolic and nucleosolic fractions from
untreated nulli SCCI cells contain little retinoic acid
or retinol binding activity, exposure of cells to reti-
noids for two hours produces an increase in nuclear
and cytosolic retinoic acid or retinol binding capacity.
Embryonal carcinoma cells of human origin derived
from the cell line Tera 2 have been also studied: they
possess a cell surface antigen SSEA 3 which can be
revealed by immunofluorescence. Andrews (42) used
this antigen as a marker of non-differentiation. Of
J. Clin. Chem. Clin. Biochem. / Vol. 26,1988 / No. 8
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the cells treated with 10 μπιοΐ/l retinoic acid for 2 to
10 days, the proportion of non-differentiated fluores-
cent cells fell to less than 20%.
Retinoic acid is therefore capable of inducing certain
morphological and biochemical modifications in un-
differentiated embryonic cells characteristic of the dif-
ferentiated state. It is interesting to note that the
concentration of retinoic acid required to induce dif-
ferentiation in human cells (1(T5 to 1(T6 mol/1) is
higher than in cells of murine origin (10~7 mol/1).
Leukaemic cells
Various lines of leukaemic cells are capable of differ-
entiating in vitro in the presence of retinoic acid. The
cellular source and experimental conditions used are
given in table 2. This differentiation can be assessed
by the following methods:
— morphological examination of cultures of pro-
myelocytic leukaemic cells,
— assessment of the capacity for phagocytosis — a
process characteristic of mature cells. Phagocytic
cells induce oxidase synthesis, which in turn pro-
duces a Superoxide anion able to reduce nitro blue
tetrazolium (NET),
— evaluation of haemoglobin synthesis,
— measurement of cholinesterase activity on cell ho-
mogenate,
— measurement of glycosyltransferase activities.
These enzymes are essential to the synthesis of the
cell surface glycoproteins which play an important
role in cell differentiation — in particular by res-
toring contact inhibition.
Garg et al. (43), working on a inurine erythroleukae-
mia cell line have shown that in culture and under
the influence of 10 μπιοΐ/ΐ retinoic acid, such cells
differentiate into nonnoblasts. Their differentiation is
characterized by an increase in the synthesis of hae^
moglobin (8 to 10 μg/106 treated cells as opposed to
0.3 to 0.8 μg/106 control cells) and an increase in
cholinesterase activity. Flynn et al. (44) have described
the effect of IS-as-retinoic acid on cells taken from
a patient suffering from acute promyelocytic leukae-
mia: 10^6 mol/1 retinoic acid induced the maturation
of promyelocytes into myelocytes, metamyelocytes
and mature polynuclear cells as shown by the micro-
scopic examination of treated cultures. The propor-
tion of cells able to reduce NET is 90% in treated
cultures and 15% in control cultures. The percentage
of polynuclear cells was higher when the patient re-
ceived pretreatment with retinoic acid (0.3 χ 10~3
mol/m? · day). Finally, the cell line HL 60 (promye-
locytes of human leukaemic origin and maintained in
culture) is frequently used in studies of cell differen-
tiation (45—48). The proportion of phagocytic cells
in the cell line HL 60 increases with the concentration .
of retinoic acid (10~8 to 10~6 mol/1) in the culture
medium. The differentiation of HL 60 cells into ma-
ture polynuclear cells following treatment with reti-
noids is accompanied by a large and rapid increase
in galactosyltransferase, fucosyltransferase and neu-
raminyltransferase activity (45). Moreover, during re-
tinoic acid-induced differentiation of HL 60 cells
along the myeloid pathway, there is a marked increase
in the activity of protamine kinase and cyclic adeno-
Tab. 2. Materials used by various authors in the study of retinoid-induced differentiation of leukaemic cells.
Authors
Garg & Brown (43)
Flynn et al. (44)
Durham et al. (45)
Fontana et al. (46)
Durham et al. (47)
Breitmann et al. (48)
Feisied et al. (75)
Olsson & Breitman (76)
Culture medium
DMEM 10% PCS*)
CMRL 10% PCS
RPMI 1640 10% PCS
RPMI 1640-inactivated
PCS
RPMI 1640 10% PCS
DMEM + HAM'S F12
10% PCS
RPMI 1640 10% PCS
DMEM + HAM'S F12
10% PCS
Retinoic
acid
Gitool/1)
10
1
1
0.1-1
1
0.001-1
1
1
Length of
treatment
(days)
5
8
4
4
5
5
• 5
2 to 8
Cell type
Murine erythroleukaemic
Human leukaemic
promyelocytes
Promyelocytes
cell line HL 60
Promyelocytes
cell line HL 60
Promyelocytes
cell line HL 60
Promyelocytes
cell line HL 60
Promyelocytes
cell line HL 60
Human histiocytic *
lymphoma cell line U 937
Cell
density
at day 0
(108/D
1-2
5
1
1
5
2.5-5
1
*) PCS = foetal calf serum
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sine 3',5'-monophosphate and phospholipid-sensitive
calcium-dependent protein kinases (46). Differentia-
tion of HL 60 into granulocytes produces a large
increase in the phosphorylation of the various sub-
strates of these enzymes, in particular of protamine
by protamine kinase contained in large quantities in
these cells (47).
Retinoic acid (10~5 to 10~8 mol/1) is the principal
retinoid used in studies of the differentiation of leu-
kaemic cells. This molecule has been shown to be one
hundred times more effective than retinol, retinal and
retinyl acetate in studies involving the cell line HL 60
(48). Retinaldehyde ati-trans, however, has an effect
twenty times greater on murine erythroleukaemic
cells. Most of the studies reported here show that the
differentiating effect is not related to any cytotoxic
phenomenon due to the retinoids (cell viability is not
affected by these compounds at the doses used). The
effects observed could be mediated by cellular retinoic
acid binding protein as in embryocarcinoma cells.
However, cellular retinoic acid binding protein has
not been detected (49) by various authors although it
may be present in the haematopoietic cells considered
at levels below the detection threshold of the methods
used; other modes of action must therefore be con-
sidered.
Melanoma cells
Melanoma cells are capable, or not, of synthesizing
melanin, depending on their degree of differentiation.
Meyskens (50) and Lotan (51) showed that following
treatment with various retinoids, cultured melanoma
cells of both human and murine origin were able to
synthesize melanin: on the two cell lines, the human
melanoma HS 939 and MIRW, the authors observed
an increase in tyrosiiiase activity and in the quantity
of intracellular melanin after seven days of treatment
with retinoic acid 10~6 mol/1. In murine melanoma
cells S 91, in addition to -all-/ran$ retinoic acid, other
retinoids, such as 13-cfa^retinoic acid and a phenyl
analogue augmented melanogenesis. On the other
hand, retinyl acetate and palmitate were ineffective.
The mechanism of action of retinoic acid would ap-
pear to be different from that of melanotropin: fol-
lowing treatment, the intracellular concentration of
cyclic AMP does not increase, contrary to what is
observed in the presence of melanotropin (52).
Retinoids therefore induce the differentiation of nor-
mal and carcinoma cells of various origins. The degree
of differentiation observed varies according to the cell
line and the nature and concentration of the retinoid
used.
Effects of vitamin A and the retinoids on cell prolifer-
ation
Normal cells
Yuspa (53) observed an increase in the mitotic index
of mouse epidermal cells cultured in the presence of
retinyl acetate (3.7 χ 10~5 mol/1). Similarly, retinoic
acid (3.3 χ 10~5 mol/1) augments the incorporation
of tritiated thymidine into newborn guinea pig epi-
dermal cells (54). The work of Hoist & Oesterhell (55)
shows that when retinol is removed from foetal calf
serum by irradiation or gel filtration the growth curve
of 3T3 fibroblasts differs little from that of similar
cells cultured under normal conditions (MEM + foe-
tal calf serum). On the other hand, other authors have
found that retinoic acid (10 μπιοΐ/ΐ) inhibits the
growth of 3T3 and 3T6 fibroblasts by 64% and 33%
respectively (56). Such discrepancies result from the
use of different experimental models.
Cells treated with a tumoural promoter
Tumoural promoters were defined from work carried
out by Berenblum (57) on mouse skin: chemical car-
cinogenesis takes place according to a two-step model
— initiation and promotion. The promoting agents,
which induce tumours in initiated cells, stimulate the
proliferation of normal cells. Retinyl acetate and re-
tinoic acid both exert an inhibiting effect on the
growth of the models studies. Thus, in human lym-
phocyte cultures treated with tetradecanoylphorbol
acetate (TPA) or phorbol dibutyrate (PDB), Abb (58)
measured the synthesis of DNA by the incorporation
of [3H]thymidine in the presence or absence of retinoic
acid (3 χ 10"6 to 3 χ 10~~4 mol/1) and observed a
50% decrease in the incorporation of [3H]thymidine
in treated cultures approximately ten hours after the
addition of the promoter and the retinoic acid.
Tumoural promoters also induce an increase in the
activity of cellular ornithine decarboxylase, the key
enzyme in the synthesis of composite polyamines
which in turn stimulate the synthesis of DNA. Ex-
periments conducted on rat kidney cells (59) and
mouse epidermal cells (60) treated with tetradeca-
noylphorbol acetate show that pretreatment with re-
tinoic acid strongly inhibits cellular ornithine decar-
boxylase activity.
Transformed cells
Studies carried out in vitro have shown that the pro-
liferation of transformed cells is inhibited to various
degrees in the presence of retinoids (1): table 3 gives
various examples which show the complexity of the
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Tab. 3. Growth inhibition by the retinoids in various types of carcinoma cells (1).
Cell type Histological state of the cell(T = transformed)
Growth inhibition (%)
Retinoic acid Retinyl acetate
Mammary cells
Mouse: adenocarcinoma
Rat: adenocarcinoma
Human: metastatic breast cancer
Melanoma cells
Mouse: clone 2 (S 91)
Human: primary tumour (HS 852)
Human: primary tumour (A 375)
Lymphoid cells
Mouse: lymphoma (BW 147)
lymphoma (EL 4)
Human: Burkitfs lymphoma
Fibroblasts
Mouse: SV 373
Human: fibrosarcoma (HT 1080)
T (spontaneously)
T (dimethylbenzanthracene)
T (spontaneously)
T spontaneously)
T (spontaneously)
T (spontaneously)
T (spontaneously)
T (benzopyrene)
T (spontaneously)
T (SV 40)
T (spontaneously)
50
75
83
83
10
69
58
33
86
10
15
·· r
40
46
57
79
10
48
42
25
68
10
16
problem since the degree of inhibition varies accord-
ing to the cell type, the origin of the transformation
and the structure of the retinoid used.
Experimental tumours
In vivo, retinoids reduce the frequency with which
various tumours appear after induction with complete
carcinogens (azaserine, benzopyrene, dimethylbenz-
anthracene 'DMBA'). Thus pancreatic tumours ap^·
pear in the Wistar rat (61) following the intra-peri-
toneal injection of azaserine and are classified as
adenomas, adenocarcinomas and invasive adenocar-
cinomas: a diet supplemented by various retinoids (1
to 2 mmol/kg of diet) over a one year period causes
a reduction in the number of invasive adenocarcino-
mas. The effect obtained is related to the structure
and the dose of the compound used. Retinyl acetate
also reduces the rate of mammary adenocarcinoma
in Sprague-Dawley rats following two injections of
methyl nitrosourea: after 60 days, 37% of the female
rats on a retinyl acetate-supplemented diet had palp-
able tumours whereas the figure was 91% in the
control group (62). Similarly, etretinate attenuates the
tumoural lesions of the skin due to the administration
of dimethylbenzanthracene (63). Finally, Verma (64)
studied the effect of retinoic acid on mouse skin
subjected successively to the action of dimethylbenz-
anthracene and tetradecanoylphorbol acetate. He
observed that the retinoid inhibited the induction of
ornithine decarboxylase activity in the epidermal cells.
Mechanisms of action
The results presented here are often contradictory and
show the complexity of the way in which retinoids
act. Various experiments have shown that the differ-
entiating role of the retinoids is related to their par-
ticipation in the biosynthesis of glycoconjugates: ·
— in vitamin Α-deficient rats, the non-differentiation
of oligomucous cells into goblet cells is accompanied
by a reduction in the synthesis of glycoproteins (17).
— Lewis (26) observed that following the supplemen-
tation of the culture medium of chondroblasts with
retinoic acid and the incorporation of [3H]mannose,
intercellular contact was maintained. In addition, au-
toradiography showed that a MT = 240000 glyco^
protein persisted, whereas it disappeared from un-
treated cultures.
The mechanism of retinoid action on the biosynthesis
of glycoconjugates would appear to be as follows:
following the phosphorylation of retinol, the retinyl
phosphate thus formed, by analogy with dolichol
phosphate, would serve as a monosaccharide acceptor
during its glycosylation by a specific glyeosyl trans-
ferase in the presence of a sugar donor molecule. The
synthesis of mannosyl and galactosyl-retmyl phos-
phate in this way has been demonstrated (65). The
mannosyl-retinyl phosphate would then act as the
donor of the mannose residue transferred to a gly^
coprotein acceptor. The ensemble of these reactions,
according to Lotan (1), might take place in the cell
membrane, thus enabling the glycosylation in situ of
the cell surface glycoproteins. However, it should be
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noted that retinol participates more actively in the
biosynthesis of glycoconjugates than retinoic acid
which does not form retinyl phosphate derivatives
(66), although retinoic acid has a stronger differen-
tiating effect than retinol; other mechanisms are thus
involved. In addition, the retinoids appear to be in-
volved in the induction of glycosyl transferases (sialyl,
fucosyl and galactosyl transferase) and might thus
modify the structure of the glycans (66, 67). By this
mechanism, vitamin A might play a role in the phe-
nomena of recognition and specific combinations be-
tween glycan structures. It would also thus be able to
modify the behaviour of cells in culture, in particular
by increasing cell attachment (68).
Finally, according to Lotan (1), certain specific gly-
cosylation reactions due to the retinoids might modify
the affinity of certain cell surface receptors for their
ligand: the retinoids could block the proliferation of
cells treated by phorbol esters by altering the ligand-
receptor affinity (69). However, the treatment of sev-
eral lines of murine cells with retinoic acid increases
epidermal growth factor (EOF) binding by increasing
the number of available receptor sites without chang-
ing the specificity of the ligand-receptor bond. The
retinoids might thus modulate cell growth by a direct
interaction with growth-factor receptors (70).
However, the effects of these substances on differen-
tiation and proliferation processes are essentially re-
lated to their intracellular metabolism. These mole-
cules bind to a high-affinity receptor present in the
cytosol and the ligand-receptor complexes move to-
ward the nucleus. The mechanism of action of the
retinoids would appear to be similar to that of the
steroid hormones: following nuclear translocation, the
complexes bind to protein molecules in particular sites
in saturable and specific way. The retinoids are then
separated from the binding protein. Bound to the
nucleus in this way, they would appear to influence
the transcription of cellular DNA by an action on the
chromatin (71, 72, 73). Thus, the human retinoic acid
receptor (hRAR) described by Petkovich et al. (12)
appears to be a retinoic acid inducible transcriptional
enhancer factor like steroid hormone receptors.
Thus, the retinoids are able to modify the activity of
various proteins. In particular, they might modulate
the level of intracellular polyamines by affecting or-
nithine decarboxylase synthesis. The induction of or-
nithine decarboxylase occurs in the middle of the Gl
phase of the cell cycle: retinoic acid inhibits the in-
duction of the enzyme, at the same time blocking the
progression of cells in the Gl phase (74). The retinoids
could also regulate cellular metabolism through their
interaction with certain protein kinases: the differen-
tiating action of retinoic acid on HL 60 cells is cor-
related with a stimulation of the activity of a protam-
ine kinase and of cyclic AMP- and Ca2+-dependent
protein kinases which play a major role in cell prolif-
eration (47).
Vitamin A and its structural analogues therefore ap-
pear to act through modifications of transcription
and biosynthesis of certain molecules, although we
are unable to distinguish clearly between the mecha-
nisms involved in cell differentiation and those in-
volved in proliferation.
At all events, the ability of the retinoids to promote
difTerentiation and to inhibit proliferation is related
to their intracellular metabolism; there is however no
simple relationship between the number of receptors
and the effect of the retinoids (35).
Conclusion
The biological activity of the retinoids can therefore
influence various aspects of cell behaviour, and this
occurs by various mechanisms:
1. Vitamin A and/or the retinoids are, in certain cases,
essential to the normal process of cell differentia-
tion.
2. They are also capable of inducing the differentia-
tion of various lines of carcinoma cells: murine
and human embryonal carcinoma cells cultured in
the presence of these compounds are able to dif-
ferentiate. Similarly, treatment with retinoids
brings several lines of leukaemic cells to maturity.
3. The retinoids generally inhibit cell proliferation.
The inhibitory effect on the growth of cells treated
either by a promoter or a carcinogen is constant.
It consists, in the first case, of a reduction in the
incorporation of [3H]thymidine into cellular DNA
and, in the second, of a reduction in the frequency
and volume of the tumours. The histological stage
of the tumours regresses and the effect is dose-
dependent.
In summary, vitamin A and its structural analogues,
through poorly-known mechanisms including modi-
fications of genome expression and of certain bio-
syntheses, are capable of controlling tissue growth
and differentiation. This effect is all the more impor-
tant since it also applies to tumoural cells and thus
holds a certain therapeutic interest.
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